Please type a plus sign (+) inside this box \rightarrow $\boxed{+}$

ENDER TOWN TOWN	Attorney Docket No. ORT-1458				
LIPITA	First Named Inventor or Application Identifier				
PATENT APPLICATION	THURMOND, Robin				
TRANSMITTAL	Express Mail		ET666296510US		
(only for new non-provisional applications under 37 CFR 1.53(b))			S. 35.		
APPLICATION ELEMENTS	ADDRESS TO:	Assistant	Commissioner for Pater		
See MPEP Chapter 600 concerning			TENT APPLICATION		
utility patent application contents.		Washing	gton, DC 20231		
1. Fee Transmittal Form (attached hereto in duplicate)		he Compu	ter Program (Appendix)		
2. Specification [Total Pages: 52]	7. Nucleotide	and/or Ān	nino Acid		
(Preferred arrangement set forth below)			(if applicable, all necessary)		
- Descriptive Title of the Invention	a. Comp				
- Cross References to Related Applications	b. X Paper	Copy (ident	ical to computer copy)		
 Statement Regarding Fed sponsored R&D Reference to Microfiche Appendix 	c. 🖂Statem	ıem veriryii	ng identity of above copies		
- Background of the Invention	ACCOMPA	NYING A	PPLICATION PARTS		
 Brief Summary of the Invention 			cover sheet & document(s))		
- Brief Description of the Drawings (if filed)	9. 37 CFR 3.	73(b) State	nent		
- Detailed Description	(when there	e is an assign	ee) Power of Attorney		
- Claim(s)	10. Tenglish T	ranslation	Document (if applicable)		
- Abstract of the Disclosure 3. Drawing(s) (35 USC 113) [Total Sheets: 5]	11. Informati				
3. Drawing(s) (35 USC 113) [Total Sheets: 5] 4. Oath or Declaration			pies of IDS Citations		
a. Newly executed (original or copy)	12. Prelimin		stcard (MPEP 503)		
b. 🗖 Unexecuted original	(Should be specif				
c. Copy from a prior application (37 CFR 1.63(d))			Priority Document(s)		
(for continuation/divisional check boxes 5 and 16)	(if foreign priorit				
Deletion of Inventor(s): Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b)	\3,5.5.8.7.18/11		•		
5. Incorporation by Reference (useable if Box 4c is checked)					
The entire disclosure of the prior application, from which a	15. X Other: I	Express M	ail Certification		
copy of the oath or declaration is supplied under Box 4c, is		_			
considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.					
16. If a CONTINUING APPLICATION, check appropriate	te box and supply th	e requisite	information:		
Amend the specification by inserting before the first line: This is a \(\sigma\) Continuation \(\sigma\) Divisional					
Continuation-in-Part (CIP) of prior application No.:, filed					
_					
17. If a DIVISIONAL APPLICATION, please cancel original Claims of the prior application before					
calculating the filing fee.					
18. Correspondence Address:					
☐ Customer Number or Bar Code Label or ☐ Correspondence Address below:					
Name: Philip S. Johnson, Esq.					
Address: Johnson & Johnson					
One Johnson & Johnson Plaza					
New Brunswick, NJ			TAT TAT 11 TTT		
19. Telephone Contact: Please direct all telephone calls or tele-faxes to John W. Wallen, III at:					
	Fax: (732) 524-2				
SIGNATURE OF APPLICANT, ATTO		T REQUI	RED		
NAME John W. Wallen, III, Esq.					
Reg. No. 35,403					
SIGNATURE MANAGEMENT	DATE	8 Novem	ber 2001		
XIVVI VVIVI					

		Complete if Known
	Application Number	N/A
FEE TRANSMITTAL	Filing Date	8 November 2001
	First Named Inventor	THURMOND
	Group Art Unit	N/A
•	Examiner Name	N/A
	Attorney Docket No.	ORT-1458

FEE CALCULATION

CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE (\$710.00)
TOTAL CLAIMS	13 - 20 =	0	X 18.00	\$ 0.00
INDEPENDENT CLAIMS	9 - 3 =	6	X 80.00	\$480.00
MULTIPLE DEPENDENT CLAIMS		N/A	\$270.00	
			TOTAL FEES	\$1190.00

METHOD OF PAYMENT

- Please charge Deposit Account No. 10-0750/ORT-1458/JWW in the amount of \$1190.00. Three copies of this sheet are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT-1458/JWW. Three copies of this sheet are enclosed.

	SUBMITTED BY:		Complete (if applicable)
Typed or Printed Name	John W. Wallen, III		Reg. No. 35,403
Signature	IM Walling	Date: 8 Nov. 2001	<u>Deposit Account</u> No. 10-0750

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Robin THURMOND, Lars KARLSSON and Sherry BAKER

FOR:

POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES OF CANINE

CATHEPSINS

Date:

8 November 2001

Express Mail Certificate

"Express Mail" mailing number:

ET666296510US

Date of Deposit:

8 November 2001

I hereby certify that this complete application, including specification pages, claims, informal drawings, sequence listing, Declaration and Power of Attorney (unsigned), and Sequence Listing diskette, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

John W. Wallen, III
(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

THURMOND, et al.

Serial No.:

N/A

Art Unit:

N/A

Filed:

8 November 2001

Examiner:

N/A

For:

POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES OF CANINE

CATHEPSIN S

Commissioner for Patents BOX: Patent Applications Washington, D.C. 20231

REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

Submitted herewith is a computer readable form of the Sequence Listing with the appropriate statements that the computer readable and paper copies are the same.

The following statements are made as required by 37 C.F.R. 1.821(f): I hereby state that the information recorded in computer readable form of the Sequence Listing is identical to the written sequence listing.

John W. Wallen, III Reg. No. 35,403

Attorney for Applicant(s)

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (858) 784-3239

DATE: 8 November 2001